These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 33022710

  • 1. Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure.
    Neven E, Corremans R, Vervaet BA, Funk F, Walpen S, Behets GJ, D'Haese PC, Verhulst A.
    Nephrol Dial Transplant; 2020 Oct 01; 35(10):1689-1699. PubMed ID: 33022710
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats.
    Phan O, Maillard M, Peregaux C, Mordasini D, Stehle JC, Funk F, Burnier M.
    J Pharmacol Exp Ther; 2013 Aug 01; 346(2):281-9. PubMed ID: 23697346
    [Abstract] [Full Text] [Related]

  • 4. PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
    Yaguchi A, Tatemichi S, Takeda H, Kobayashi M.
    PLoS One; 2017 Aug 01; 12(7):e0180430. PubMed ID: 28704404
    [Abstract] [Full Text] [Related]

  • 5. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Sucroferric Oxyhydroxide Study Group.
    Nephrol Dial Transplant; 2015 Jun 01; 30(6):1037-46. PubMed ID: 25691681
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM, Floege J.
    Expert Opin Pharmacother; 2018 Jul 01; 19(10):1137-1148. PubMed ID: 29985725
    [Abstract] [Full Text] [Related]

  • 11. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease.
    Geisser P, Philipp E.
    Clin Nephrol; 2010 Jul 01; 74(1):4-11. PubMed ID: 20557860
    [Abstract] [Full Text] [Related]

  • 12. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
    Cernaro V, Santoro D, Lacquaniti A, Costantino G, Visconti L, Buemi A, Buemi M.
    Int J Nephrol Renovasc Dis; 2016 Jul 01; 9():11-9. PubMed ID: 26893577
    [Abstract] [Full Text] [Related]

  • 13. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A, Al-Makki A, Sutton J, Shepler B.
    Clin Ther; 2014 Dec 01; 36(12):2082-2093. PubMed ID: 25450474
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F, Terao A.
    Clin Exp Nephrol; 2017 Jun 01; 21(3):513-522. PubMed ID: 27389681
    [Abstract] [Full Text] [Related]

  • 16. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL, Plosker GL.
    Drugs; 2015 Apr 01; 75(5):533-42. PubMed ID: 25761962
    [Abstract] [Full Text] [Related]

  • 17. Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.
    Koiwa F, Yokoyama K, Fukagawa M, Akizawa T.
    J Ren Nutr; 2017 Sep 01; 27(5):346-354. PubMed ID: 28550969
    [Abstract] [Full Text] [Related]

  • 18. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
    Neven E, Vervaet B, Brand K, Gottwald-Hostalek U, Opdebeeck B, De Maré A, Verhulst A, Lalau JD, Kamel S, De Broe ME, D'Haese PC.
    Kidney Int; 2018 Jul 01; 94(1):102-113. PubMed ID: 29716795
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.
    Yaguchi A, Akahane K, Tsuchioka K, Yonekubo S, Yamamoto S, Tamai Y, Tatemichi S, Takeda H.
    BMC Nephrol; 2019 Dec 12; 20(1):465. PubMed ID: 31830936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.